491 related articles for article (PubMed ID: 30366101)
1. Pharmacological targeting of RAS: Recent success with direct inhibitors.
O'Bryan JP
Pharmacol Res; 2019 Jan; 139():503-511. PubMed ID: 30366101
[TBL] [Abstract][Full Text] [Related]
2. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
4. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of RAS: New hope for drugging the "undruggable".
Khan I; Rhett JM; O'Bryan JP
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118570. PubMed ID: 31678118
[TBL] [Abstract][Full Text] [Related]
6. RAS-targeted therapies: is the undruggable drugged?
Moore AR; Rosenberg SC; McCormick F; Malek S
Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
[TBL] [Abstract][Full Text] [Related]
7. The Endeavours in RAS Inhibition - the Past, Present, and Future.
Hussain J; Kirubakaran S; Ravi S
Curr Top Med Chem; 2020; 20(29):2708-2722. PubMed ID: 32885752
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC; Huang PH; Kulp SK; Chen CS
Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
[TBL] [Abstract][Full Text] [Related]
9. Direct inhibition of RAS: Quest for the Holy Grail?
Spencer-Smith R; O'Bryan JP
Semin Cancer Biol; 2019 Feb; 54():138-148. PubMed ID: 29248537
[TBL] [Abstract][Full Text] [Related]
10. Probing RAS Function with Monobodies.
Khan I; O'Bryan JP
Methods Mol Biol; 2021; 2262():281-302. PubMed ID: 33977484
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
12. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
13. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Coley AB; Ward A; Keeton AB; Chen X; Maxuitenko Y; Prakash A; Li F; Foote JB; Buchsbaum DJ; Piazza GA
Adv Cancer Res; 2022; 153():131-168. PubMed ID: 35101229
[TBL] [Abstract][Full Text] [Related]
14. Blocking Ras inhibition as an antitumor strategy.
Marín-Ramos NI; Ortega-Gutiérrez S; López-Rodríguez ML
Semin Cancer Biol; 2019 Feb; 54():91-100. PubMed ID: 29409706
[TBL] [Abstract][Full Text] [Related]
15. Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.
Michael JV; Goldfinger LE
Semin Cancer Biol; 2019 Feb; 54():121-130. PubMed ID: 29203271
[TBL] [Abstract][Full Text] [Related]
16. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
17. Biology, pathology, and therapeutic targeting of RAS.
Rhett JM; Khan I; O'Bryan JP
Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
[TBL] [Abstract][Full Text] [Related]
18. The reactivity-driven biochemical mechanism of covalent KRAS
Hansen R; Peters U; Babbar A; Chen Y; Feng J; Janes MR; Li LS; Ren P; Liu Y; Zarrinkar PP
Nat Struct Mol Biol; 2018 Jun; 25(6):454-462. PubMed ID: 29760531
[TBL] [Abstract][Full Text] [Related]
19. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
20. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]